IL292889A - Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies - Google Patents

Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies

Info

Publication number
IL292889A
IL292889A IL292889A IL29288922A IL292889A IL 292889 A IL292889 A IL 292889A IL 292889 A IL292889 A IL 292889A IL 29288922 A IL29288922 A IL 29288922A IL 292889 A IL292889 A IL 292889A
Authority
IL
Israel
Prior art keywords
riu0003
wkhu0003
ruu0003
khu0003
dqu0003
Prior art date
Application number
IL292889A
Other languages
English (en)
Hebrew (he)
Inventor
Christine Morel Coquery
Jonathon Andrew Kluft
Iii William Thomas Symonds
Original Assignee
Immunovant Sciences Gmbh
Christine Morel Coquery
Jonathon Andrew Kluft
Iii William Thomas Symonds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovant Sciences Gmbh, Christine Morel Coquery, Jonathon Andrew Kluft, Iii William Thomas Symonds filed Critical Immunovant Sciences Gmbh
Publication of IL292889A publication Critical patent/IL292889A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL292889A 2019-11-19 2020-11-18 Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies IL292889A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962937395P 2019-11-19 2019-11-19
PCT/US2020/061028 WO2021101975A1 (en) 2019-11-19 2020-11-18 Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies

Publications (1)

Publication Number Publication Date
IL292889A true IL292889A (en) 2022-07-01

Family

ID=73854886

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292889A IL292889A (en) 2019-11-19 2020-11-18 Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies

Country Status (10)

Country Link
US (1) US20230049011A1 (cg-RX-API-DMAC7.html)
EP (1) EP4061486A1 (cg-RX-API-DMAC7.html)
JP (1) JP7722991B2 (cg-RX-API-DMAC7.html)
CN (1) CN114728180A (cg-RX-API-DMAC7.html)
AU (1) AU2020387399A1 (cg-RX-API-DMAC7.html)
CA (1) CA3157797A1 (cg-RX-API-DMAC7.html)
IL (1) IL292889A (cg-RX-API-DMAC7.html)
MX (1) MX2022005862A (cg-RX-API-DMAC7.html)
TW (1) TW202132346A (cg-RX-API-DMAC7.html)
WO (1) WO2021101975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117693523A (zh) * 2021-08-13 2024-03-12 舒泰神(北京)生物制药股份有限公司 特异性识别fcrn的抗体及其用途
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
JP2025528527A (ja) * 2022-09-06 2025-08-28 イミュノバント・サイエンシズ・ゲーエムベーハー 抗FcRN抗体を用いたグレーブス病の治療方法
WO2026136830A1 (en) * 2024-12-20 2026-06-25 Paragon Therapeutics, Inc. Anti-fcrn antibodies and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) * 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド FcRn抗体およびその使用方法
CA3022547A1 (en) * 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
BR112019001806A2 (pt) * 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
EP3762027A4 (en) * 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES

Also Published As

Publication number Publication date
CA3157797A1 (en) 2021-05-27
MX2022005862A (es) 2022-06-23
AU2020387399A1 (en) 2022-05-19
CN114728180A (zh) 2022-07-08
US20230049011A1 (en) 2023-02-16
TW202132346A (zh) 2021-09-01
WO2021101975A1 (en) 2021-05-27
EP4061486A1 (en) 2022-09-28
JP7722991B2 (ja) 2025-08-13
JP2023502398A (ja) 2023-01-24
KR20220100880A (ko) 2022-07-18

Similar Documents

Publication Publication Date Title
Yoshihara et al. Chemical interaction of glycero-phosphate dimethacrylate (GPDM) with hydroxyapatite and dentin
Yoshihara et al. Nano-controlled molecular interaction at adhesive interfaces for hard tissue reconstruction
DE102008042212A1 (de) Reflektives optisches Element und Verfahren zu seiner Herstellung
EP1318844B1 (de) Oberflächenmodifizierte implantate
Bosco et al. Hydroxyapatite nanocrystals functionalized with alendronate as bioactive components for bone implant coatings to decrease osteoclastic activity
IL275004B2 (en) Battery swapping station and control method therefor
KR102497107B1 (ko) 플로라이드(Flouride)로 도핑되고 구연산염으로 코팅된 비정질 인산칼슘 나노입자를 얻기 위한 공정
AU2003210787A1 (en) Phosphorus-containing compounds & uses thereof
EA011488B1 (ru) Фосфорсодержащие соединения и их получение
EP3253740A1 (en) Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
KR20110059546A (ko) 스트론튬 염,비타민 d 및 시클로덱스트린을 포함하는 약제 조성물
JP3853785B2 (ja) 口腔用組成物
EP3663264A1 (en) Method for producing zirconia particle-containing powder
Cunha-Filho et al. Characterization of β-lapachone and methylated β-cyclodextrin solid-state systems
EP1603525B1 (en) Oral preparation system
WO2022089885A1 (de) Optisches element, insbesondere zur reflexion von euv-strahlung, optische anordnung und verfahren zum herstellen eines optischen elements
CA2480125C (en) Use of carbon-2-modified-19-nor-vitamin d analogs to induce the formation of new bone
DE102022203644A1 (de) Verfahren zum Herstellen eines Substrats und eines reflektiven optischen Elements für die EUV-Lithographie
EP2773629B1 (en) Process for the preparation of an amorphous form of cabazitaxel
IL292204B2 (en) A conveyor device for at least transferring a liquid and a pump comprising such a conveyor device
WO1999031112A1 (de) Vitamin d-derivate mit phosphoratomen in den seitenketten
Sternitzke et al. Strontium hydroxyapatite and strontium carbonate as templates for the precipitation of calcium-phosphates in the absence and presence of fluoride
WO2010043215A1 (de) Verfahren zur herstellung photokatalytisch aktiver titandioxidschichten
IL276083B2 (en) Security door mounting arrangement
US20010051738A1 (en) Crystalline1alpha,24(S)-dihydroxyvitamin D2 and method of purification thereof